

BSR & Co. LLP

Chartered Accountants

14th Floor, Central B Wing and North C Wing,
Nesco IT Park 4, Nesco Center,
Western Express Highway,
Goregaon (East), Mumbai - 400 063

Telephone: +91 22 6257 1000
Fax: +91 22 6257 1010


Limited Review Report on Unaudited Quarterly Standalone Financial Results of Wockhardt Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To the Board of Directors of Wockhardt Limited

1. We have reviewed the accompanying Statement of unaudited standalone financial results of Wockhardt Limited ("the Company") for the quarter ended 30 June 2021 ("the Statement").
2. This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Attention is drawn to the fact that the figures for the three months ended 31 March 2021 as reported in these financial results are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of the previous financial year had only been reviewed and not subjected to audit.
5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For BSR & Co. LLP
Chartered Accountants

Firm's Registration No: 101248W/W-100022



Koosai Leheri
Partner

Mumbai
22 July 2021

Membership No: 112399
UDIN: 21112399AAAACF7087

Registered Office:

WOCKHARDT LIMITED

Registered Office: D-4 MIDC, Chikalthana, Aurangabad - 431 006

Global Headquarters: Wockhardt Towers, Bandra Kurla Complex, Bandra (East), Mumbai 400 051

CIN:L24230MH1999PLC120720

Tel: 91 22 2653 4444 ; Fax: 91 22 2652 3905; e-mail id : investorrelations@wockhardt.com; Website: www.wockhardt.com

(Rs. In Crore except per share data)

STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER ENDED JUNE 30, 2021

PARTICULARS	3 MONTHS ENDED 30/06/2021	3 MONTHS ENDED 31/03/2021	3 MONTHS ENDED 30/06/2020	YEAR ENDED 31/03/2021
	Unaudited	Audited (Refer Note 4)	Unaudited	Audited
(Refer notes below)				
1 Income from Continuing operations				
(a) Revenue from Continuing operations	278.95	261.75	177.58	987.26
(b) Other income	3.15	6.31	9.74	40.73
Total income	282.10	268.06	187.32	1,027.99
2 Expenses from Continuing operations				
(a) Cost of materials consumed	67.42	59.02	10.68	253.10
(b) Purchase of stock-in-trade	39.84	38.70	50.43	164.97
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(0.31)	25.96	14.85	(1.78)
(d) Employee benefits expense	72.68	58.25	82.08	293.36
(e) Finance costs	55.43	45.46	58.61	200.24
(f) Depreciation and amortisation expense	42.47	52.31	46.08	184.08
(g) Exchange fluctuation loss / (gain), net	(12.47)	(1.95)	3.30	28.70
(h) Other expenses	94.61	103.55	111.79	386.61
Total expenses	359.67	381.30	377.82	1,509.28
3 Loss before exceptional items and tax from Continuing operations (1-2)	(77.57)	(113.24)	(190.50)	(481.29)
4 Discontinued operations				
Profit before exceptional items and tax from Discontinued operations	-	-	13.87	13.87
5 Exceptional items - credit/(charge)				
a) Continuing operations	-	-	(142.48)	(142.48)
b) Discontinued operations - Refer note 2	-	-	1,470.32	1,470.32
Total- Exceptional items	-	-	1,327.84	1,327.84
6 Loss after exceptional items before tax from Continuing operations (3 ± 5a)	(77.57)	(113.24)	(332.98)	(623.77)
7 Tax expense of Continuing operations:				
Current tax - credit	-	(28.36)	(69.89)	(136.80)
Deferred tax - credit - (Net)	(28.88)	(37.83)	(44.15)	(94.93)
8 Net Loss from Continuing operations (6 ± 7)	(48.69)	(47.05)	(218.94)	(382.04)
9 Profit after exceptional items before tax from Discontinued operations (4 ± 5b)	-	-	1,484.19	1,484.19
10 Tax expense of Discontinued operations:				
Current tax - charge	-	-	311.49	311.49
Deferred tax - charge - (Net)	-	-	187.37	187.37
11 Profit from Discontinued operations (9 ± 10)	-	-	985.33	985.33
12 Profit / (Loss) for the period (8 ± 11)	(48.69)	(47.05)	766.39	593.29
13 Other Comprehensive Income				
a) Other Comprehensive Income - Continuing operations				
i) Items that will not be reclassified to Profit or Loss - (charge)/credit (consisting of re-measurement of net defined benefit (liability)/asset)	(0.11)	(4.99)	2.05	(0.43)
ii) Income tax relating to items that will not be reclassified to Profit or Loss - credit/(charge)	0.04	1.73	(0.71)	0.14
iii) Other Comprehensive Income (net of tax) from Continuing operations	(0.07)	(3.26)	1.34	(0.29)
b) Other Comprehensive Income - Discontinued operations				
i) Items that will not be reclassified to Profit or Loss - (charge)/credit (consisting of re-measurement of net defined benefit (liability)/asset)	-	-	(0.04)	(0.04)
ii) Income tax relating to items that will not be reclassified to Profit or Loss - credit/(charge)	-	-	0.01	0.01
iii) Other Comprehensive Income (net of tax) from Discontinued operations	-	-	(0.03)	(0.03)
Total Comprehensive Income [12 ± 13a(iii) ± 13b(iii)]	(48.78)	(50.31)	767.70	592.97
14 Paid-up equity share capital (face value of Rs. 5/- each)	55.39	55.39	55.37	55.39
15 Other Equity excluding Revaluation Reserves as per balance sheet				1,550.37
16 Earnings per share for Continuing operations (face value of Rs. 5/- each) (*not annualised)				
(a) Basic (Rs.)	(4.40)*	(4.25)*	(19.77)*	(35.40)
(b) Diluted (Rs.)	(4.40)*	(4.25)*	(19.77)*	(35.40)
Earnings per share for Discontinued operations (face value of Rs. 5/- each) (*not annualised)				
(a) Basic (Rs.)	-	-	88.98*	88.97
(b) Diluted (Rs.)	-	-	88.64*	88.58
Earnings per share for Continuing and Discontinued operations (face value of Rs. 5/- each) (*not annualised)				
(a) Basic (Rs.)	(4.40)*	(4.25)*	69.21*	53.57
(b) Diluted (Rs.)	(4.40)*	(4.25)*	68.94*	53.34

Notes To Standalone Results :-


- 1) The results were reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on July 22, 2021. The results have been subjected to limited review by the Statutory Auditors of the Company.
- 2) The Board of Directors, in their meeting held on June 09, 2020, concluded the Business transfer agreement ("BTA") entered into between the Company and Dr. Reddy's Laboratories Limited ("Purchaser") dated February 12, 2020 read with amendments made time to time for the transfer of the business comprising 62 products and line extensions along with related assets and liabilities, contracts, permits, intellectual properties, employees, marketing, sales and distribution of the same in the Domestic Branded Division in India, Nepal, Bhutan, Sri Lanka and Maldives, and the manufacturing facility at Baddi, Himachal Pradesh, where some of the products which are being transferred were manufactured (together the "Business Undertaking"), to the Purchaser. The consideration for the above said transfer of Business Undertaking for Rs. 1,850 crore was structured as per following :
 - a) an amount equal to Rs. 1,550 crore (including a deposit of Rs. 67 crore in escrow account towards adjustments for, inter alia, Net working capital, employee liabilities and certain other contractual and statutory liabilities) to be paid on the Closing Date under the BTA. The said amount has been paid by the Purchaser to the Company during the year ended March 31, 2021 including release of Rs. 63 crore out of the original escrow account of Rs. 67 crore and,
 - b) balance amount equal to Rs. 300 crore out of total consideration of Rs. 1,850 crore has been held back ("Holdback Amount"), by the Purchaser on the Closing Date (i.e., June 09, 2020) for assessment of the impact of the COVID-19 pandemic on the Business Undertaking and shall be released as equal to 2 (two) times the amount by which the revenue exceeds Rs. 480 crore from sales of the products forming part of the said Business Undertaking by the Purchaser during the 12 months post-closing date.

The profit from aforesaid Transfer of Business Undertaking (excluding the Holdback Amount of Rs. 300 crore) amounting to Rs. 1,470.32 crore had been shown as 'Exceptional Items - Discontinued operations during the year ended March 31, 2021'.

The Company and Purchaser, in accordance with the BTA, are in the process of determining the value of the Holdback Amount receivable, if any, by the Company. Pending determination of such amount between the parties, no gain has been recognised in the Profit and Loss account in the quarter ended June 30, 2021.
- 3) The Company continues to monitor the impact of COVID-19 on its businesses across the globe, its customers, vendors, employees, productions, supply chain and logistics etc. The Company has exercised due care in significant accounting judgements and estimates in relation to recoverability of receivables, investments and inventories based on the information available to date, both internal and external, while preparing the Company's financial results for the current period.
- 4) Figures for the quarter ended March 31, 2021 are the balancing figures between the audited figures in respect of the full financial year and the reviewed figures upto the third quarter of the financial year 2020-21.
- 5) The Company is exclusively into Pharmaceutical business Segment.
- 6) Previous period / year figures have been recast / re-grouped to conform to the current year's presentation.


Mumbai
Date : July 22, 2021

FOR WOCKHARDT LIMITED



H F KHORAKIWALA

CHAIRMAN
DIN: 00045608



B S R & Co. LLP

Chartered Accountants

14th Floor, Central B Wing and North C Wing,
Nesco IT Park 4, Nesco Center,
Western Express Highway,
Goregaon (East), Mumbai - 400 063

Telephone: +91 22 6257 1000
Fax: +91 22 6257 1010

Limited Review Report on Unaudited Quarterly Consolidated Financial Results of Wockhardt Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To the Board of Directors of
Wockhardt Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Wockhardt Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the quarter ended 30 June 2021 ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").
2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the financial information of the following entities:

Name of the Entity	Relationship
1) Wockhardt UK Holdings Limited (including its following subsidiaries and its step-down subsidiaries) a) Wallis Group Limited b) The Wallis Laboratory Limited c) Wallis Licensing Limited d) Wockhardt Farmaceutica Do Brasil Ltda	Wholly Owned Subsidiary

Wockhardt Limited

22 July 2021

Page 2 of 3

Limited Review Report on Unaudited Quarterly Consolidated Financial Results of Wockhardt Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Continued)**Wockhardt Limited**

Name of the Entity	Relationship
2) Wockhardt Infrastructure Development Limited	Wholly Owned Subsidiary
3) Wockhardt Europe Limited (including its following wholly owned subsidiary) a) Wockhardt Nigeria Limited	Wholly Owned Subsidiary
4) Wockhardt Medicines Limited	Wholly Owned Subsidiary
5) Wockhardt Bio AG (including its following subsidiaries and its step-down subsidiaries) a) CP Pharmaceuticals Limited b) CP Pharma (Schweiz) AG c) Z & Z Services GmbH d) Wockhardt UK Limited e) Wockpharma Ireland Limited f) Pinewood Laboratories Limited g) Pinewood Healthcare Limited h) Laboratories Negma S.A.S. i) Wockhardt France (Holdings) S.A.S. j) Wockhardt Holding Corp. k) Wockhardt USA LLC l) Morton Grove Pharmaceuticals Inc. m) MGP Inc. n) Laboratories Pharma 2000 S.A.S. o) Niverpharma S.A.S. p) Negma Beneulex S.A. q) Phytex S.A.S. r) Wockhardt Farmaceutica SA DE CV s) Wockhardt Services SA DE CV t) Wockhardt Bio (R) LLC u) Wockhardt Bio Pty Limited v) Wockhardt Bio Limited	Subsidiary

5. Attention is drawn to the fact that the figures for the three months ended 31 March 2021 as reported in these financial results are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of the previous financial year had only been reviewed and not subjected to audit.



Limited Review Report on Unaudited Quarterly Consolidated Financial Results of Wockhardt Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Continued)

Wockhardt Limited

6. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
7. We did not review the interim financial information of five subsidiaries included in the Statement, whose interim financial information reflect total revenues (before consolidation adjustments) of Rs 794.31 crores, total net profit after tax (before consolidation adjustments) of Rs 142.70 crores and total comprehensive income (before consolidation adjustments) of Rs 137.99 crores, for the quarter ended 30 June 2021, as considered in the Statement. These interim financial information have been reviewed by other auditors whose reports have been furnished to us by the management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of the above matter.

8. The Statement includes the interim financial information of twenty-one subsidiaries which have not been reviewed, whose interim financial information reflect total revenue (before consolidation adjustments) of Rs 30.26 crores, total net profit after tax (before consolidation adjustments) of Rs 0.84 crores and total comprehensive income (before consolidation adjustments) of Rs 0.84 crores for the quarter ended 30 June 2021, as considered in the Statement. According to the information and explanations given to us by the management, these interim financial information are not material to the Group.

Our conclusion on the Statement is not modified in respect of the above matter.

For **BSR & Co. LLP**
Chartered Accountants

Firm's Registration No: 101248W/W-100022

Koosai Leher
Partner

Membership No: 112399

ICAI UDIN:21112399AAAACG7746

WOCKHARDT LIMITED

Registered Office: D-4 MIDC, Chikalthana, Aurangabad - 431 006
Global Headquarters: Wockhardt Towers, Bandra Kurla Complex, Bandra (East), Mumbai 400 051
CIN: L24230MH1999PLC120720
Tel: 91 22 2653 4444; Fax: 91 22 2652 3905; e-mail id: investorrelations@wockhardt.com, Website: www.wockhardt.com

(Rs. in Crore except per share data)

STATEMENT OF CONSOLIDATED UNAUDITED RESULTS FOR THE QUARTER ENDED JUNE 30, 2021

PARTICULARS	3 MONTHS ENDED 30/06/2021	3 MONTHS ENDED 31/03/2021	3 MONTHS ENDED 30/06/2020	YEAR ENDED 31/03/2021
	Unaudited	Audited (Refer Note 6)	Unaudited	Audited
(Refer Notes Below)				
1 Income from Continuing Operations				
(a) Revenue from Continuing operations	859.55	631.96	598.27	2,708.30
(b) Other income	1.65	7.54	7.95	132.27
Total income	861.20	639.50	606.22	2,840.57
2 Expenses from Continuing Operations				
(a) Cost of materials consumed	150.46	171.91	116.99	682.43
(b) Purchase of stock-in-trade	142.55	109.20	159.07	579.90
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	30.66	28.16	(57.77)	(126.84)
(d) Employee benefits expense	192.26	161.25	202.49	762.95
(e) Finance costs	64.10	54.63	73.70	249.08
(f) Depreciation and amortisation expense	64.34	65.03	55.96	246.02
(g) Exchange fluctuation loss / (gain), net	(13.25)	(14.20)	8.66	2.46
(h) Other expenses	236.08	241.70	240.88	870.43
Total expenses	867.20	817.68	799.98	3,266.43
3 Loss before exceptional items and tax from Continuing Operations (1-2)	(6.00)	(178.18)	(193.76)	(425.86)
4 Discontinued Operations				
Profit before exceptional items and tax from Discontinued Operations	-	-	13.87	13.87
5 Exceptional items - credit/(charge)				
a) Continuing Operations	-	-	(142.48)	(142.48)
b) Discontinued Operations - (Refer note 3)	-	-	1,470.32	1,470.32
Total Exceptional Items	-	-	1,327.84	1,327.84
6 Loss after exceptional items before tax from Continuing Operations (3 ± 5a)	(6.00)	(178.18)	(336.24)	(568.34)
7 Tax expense of continuing operations :				
Current tax - (credit)/charge	9.03	(32.41)	(66.12)	(120.82)
Deferred tax - credit	(8.45)	(38.93)	(44.54)	(150.79)
8 Net Loss from Continuing Operations (6 ± 7)	(6.58)	(106.84)	(225.58)	(296.73)
9 Profit after exceptional items before tax from Discontinued Operations (4 ± 5b)	-	-	1,484.19	1,484.19
10 Tax expense of discontinued operations:				
Current tax - charge	-	-	311.49	311.49
Deferred tax - charge (Net)	-	-	187.37	187.37
11 Profit from Discontinued Operations (9 ± 10)	-	-	985.33	985.33
12 Profit / (Loss) for the period (8 ± 11)	(6.58)	(106.84)	759.75	688.60
Attributable to :				
Equity shareholders of the Company	(12.71)	(92.79)	760.06	686.06
Non - Controlling Interest	6.13	(14.05)	(0.31)	2.54
13 Other Comprehensive Income from Continuing Operations				
(a) Items that will not be reclassified to Profit or Loss - (charge)/ credit (consisting of re-measurement of net defined benefit (liability) / asset)	(5.93)	(25.98)	1.12	(23.21)
(b) Income tax relating to items that will not be reclassified to Profit or Loss - (charge)/ credit	1.15	5.72	(0.54)	4.47
(c) Items that will be reclassified to Profit or Loss - (charge)/ credit (Consisting of Exchange differences on translating the financial statements of foreign operations)	50.42	(35.61)	14.07	14.79
(d) Other Comprehensive Income (Net of tax) from continuing operations (a ± b ± c)	45.64	(55.87)	14.65	(3.95)
14 Other Comprehensive Income from Discontinued Operations				
(a) Items that will not be reclassified to Profit or Loss - (charge)/ credit (consisting of re-measurement of net defined benefit (liability)/ asset)	-	-	(0.04)	(0.04)
(b) Income tax relating to items that will not be reclassified to Profit or Loss - (charge)/ credit	-	-	0.01	0.01
(c) Other Comprehensive Income (Net of tax) from discontinued operations (a ± b)	-	-	(0.03)	(0.03)
15 Total Comprehensive Income (12 ± 13 (d) ± 14 (c))	39.06	(162.71)	774.37	684.62
Attributable to :				
Equity shareholders of the Company	24.46	(149.07)	771.85	686.92
Non - Controlling Interest	14.60	(13.64)	2.52	(2.30)
16 Paid-up equity share capital (face value of Rs. 5/- each)	55.39	55.39	55.37	55.39
17 Other Equity excluding Revaluation Reserves as per Balance Sheet				3,321.37
18 Earnings per equity share for continuing operations (face value of Rs. 5/- each) (*not annualised)				
(a) Basic (Rs.)	(1.15)*	(8.38)*	(20.34)*	(27.02)
(b) Diluted (Rs.)	(1.15)*	(8.38)*	(20.34)*	(27.02)
Earnings per equity share for discontinued operations (face value of Rs. 5/- each) (*not annualised)				
(a) Basic (Rs.)	-	-	88.98*	88.97
(b) Diluted (Rs.)	-	-	88.64*	88.58
Earnings per equity share for continuing and discontinued operations (face value of Rs. 5/- each) (*not annualised)				
(a) Basic (Rs.)	(1.15)*	(8.38)*	68.64*	61.95
(b) Diluted (Rs.)	(1.15)*	(8.38)*	68.37*	61.68

Notes To Consolidated Results:-

- 1) The results were reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on July 22, 2021. The results have been subjected to limited review by the Statutory Auditors of the Company.
- 2) The Consolidated Results relate to Wockhardt Limited ('the Company' or 'the Holding Company') and its Subsidiaries (together constitute 'the Group') and are prepared by applying Ind AS 110 - "Consolidated Financial Statements".
- 3) The Board of Directors, in their meeting held on June 09, 2020, concluded the Business transfer agreement ("BTA") entered into between the Company and Dr. Reddy's Laboratories Limited ("Purchaser") dated February 12, 2020 read with amendments made time to time for the transfer of the business comprising 62 products and line extensions along with related assets and liabilities, contracts, permits, intellectual properties, employees, marketing, sales and distribution of the same in the Domestic Branded Division in India, Nepal, Bhutan, Sri Lanka and Maldives, and the manufacturing facility at Baddi, Himachal Pradesh, where some of the products which are being transferred were manufactured (together the "Business Undertaking"), to the Purchaser. The consideration for the above said transfer of Business Undertaking for Rs. 1,850 crore was structured as per following :

a) an amount equal to Rs. 1,550 crore (including a deposit of Rs. 67 crore in escrow account towards adjustments for, inter alia, Net working capital, employee liabilities and certain other contractual and statutory liabilities) to be paid on the Closing Date under the BTA. The said amount has been paid by the Purchaser to the Company during the year ended March 31, 2021 including release of Rs. 63 crore out of the original escrow account of Rs.67 crore and,

b) balance amount equal to Rs. 300 crore out of total consideration of Rs. 1,850 crore has been held back ("Holdback Amount"), by the Purchaser on the Closing Date (i.e., June 09, 2020) for assessment of the impact of the COVID-19 pandemic on the Business Undertaking and shall be released as equal to 2 (two) times the amount by which the revenue exceeds Rs. 480 crore from sales of the products forming part of the said Business Undertaking by the Purchaser during the 12 months post-closing date.

The profit from aforesaid Transfer of Business Undertaking (excluding the Holdback Amount of Rs. 300 crore) amounting to Rs. 1,470.32 crore had been shown as 'Exceptional Items - discontinued operations' during the year ended March 31, 2021.

The Company and Purchaser, in accordance with the BTA, are in the process of determining the value of the Holdback Amount receivable, if any, by the Company. Pending determination of such amount between the parties, no gain has been recognised in the Profit and Loss account in the Quarter ended June 30, 2021.

4) **Key Financials on Standalone basis:**


(Rs. in Crore)

PARTICULARS	3 MONTHS ENDED 30/06/2021	3 MONTHS ENDED 31/03/2021	3 MONTHS ENDED 30/06/2020	YEAR ENDED 31/03/2021
	Unaudited	Audited	Unaudited	Audited
Total Income (continuing operation)	282.10	268.06	187.32	1,027.99
Loss before tax from continuing operation	(77.57)	(113.24)	(332.98)	(623.77)
Loss after tax from continuing operation	(48.69)	(47.05)	(218.94)	(392.04)
Profit before tax from discontinued operation	-	-	1,484.19	1,484.19
Profit after tax from discontinued operation	-	-	985.33	985.33

Note: The unaudited standalone results have been filed with the Stock Exchanges under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and are available on the Stock Exchanges websites (www.nseindia.com and www.bseindia.com) and also on the Company's website www.wockhardt.com.

- 5) The Group continues to monitor the impact of COVID-19 on its businesses across the globe, its customers, vendors, employees, productions, supply chain and logistics etc. The Group has exercised due care in significant accounting judgements and estimates in relation to recoverability of receivables, investments and inventories based on the information available to date, both internal and external, while preparing the Group's financial results for the current period.
- 6) Figures for the quarter ended March 31, 2021 are the balancing figures between the audited figures in respect of the full financial year and the reviewed figures upto the third quarter of the financial year 2020-21.
- 7) The Group is exclusively into Pharmaceutical business Segment.
- 8) For List of Subsidiaries as on June 30, 2021 please refer Annexure.
- 9) Previous period / year figures have been recast / re-grouped to conform to the current year's presentation.

FOR WOCKHARDT LIMITED



H F KHORAKIWALA
CHAIRMAN
DIN: 00045608

Mumbai
Date : July 22, 2021



WOCKHARDT LIMITED

Registered Office: D-4 MIDC, Chikalthana, Aurangabad - 431 006

Global Headquarters: Wockhardt Towers, Bandra Kurla Complex, Bandra (East), Mumbai 400 051

Annexure to Note 8 of Consolidated unaudited Results for the Quarter ended June 30, 2021

List of Subsidiaries as on June 30, 2021

- 1 Wockhardt UK Holdings Limited
- 2 CP Pharmaceuticals Limited
- 3 CP Pharma (Schweiz) AG
- 4 Wallis Group Limited
- 5 The Wallis Laboratory Limited
- 6 Wockhardt Farmaceutica Do Brasil Ltda
- 7 Wallis Licensing Limited
- 8 Wockhardt Infrastructure Development Limited
- 9 Z & Z Services GmbH
- 10 Wockhardt Europe Limited
- 11 Wockhardt Nigeria Limited
- 12 Wockhardt USA LLC
- 13 Wockhardt UK Limited
- 14 Wockpharma Ireland Limited
- 15 Pinewood Laboratories Limited
- 16 Pinewood Healthcare Limited
- 17 Laboratoires Negma S.A.S.
- 18 Wockhardt France (Holdings) S.A.S.
- 19 Wockhardt Holding Corp.
- 20 Morton Grove Pharmaceuticals Inc.
- 21 MGP Inc.
- 22 Laboratoires Pharma 2000 S.A.S.
- 23 Niverpharma S.A.S.
- 24 Negma Beneulex S.A.
- 25 Phytex S.A.S.
- 26 Wockhardt Farmaceutica SA DE CV
- 27 Wockhardt Services SA DE CV
- 28 Wockhardt Bio AG
- 29 Wockhardt Bio (R) LLC
- 30 Wockhardt Bio Pty Limited
- 31 Wockhardt Bio Limited
- 32 Wockhardt Medicines Limited

